Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NMPA Approval

Ranibizumab Injections

Approval Number

国药准字SJ20170003

CompanyNovartis Pharma Schweiz AG

Registration Date

September 16, 2021

Previous Approval Numbers

S20170003

Drug Information

Generic Name

雷珠单抗注射液

Trade Name

诺适得

Brand Name

诺适得

Dosage Form

注射剂

Strength

10mg/ml,每瓶装量0.20ml

Drug Type

生物制品

Registration Date

September 16, 2021

Expiry Date

September 15, 2026

Company Information

Applicant Company

Company NameNovartis Pharma Schweiz AG

Company Address

6343 Risch, Switzerland

Manufacturing Company

Company NameNovartis Pharma Stein AG

Company Address

Schaffhauserstrasse 4332 Stein, Switzerland

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy

雷珠单抗注射液 - NMPA 批准文号 | MedPath